Edwards Lifesciences
Open
$81.43
Prev. Close
$81.34
High
$81.47
Low
$81.43
Market Snapshot
$47.11B
43.9
7.00
$5.44B
Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. The company is headquartered in Irvine, California and currently employs 16,000 full-time employees. The company went IPO on 2000-03-27. The firm partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. The company provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. The company is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
emptyResult
Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. The company is headquartered in Irvine, California and currently employs 16,000 full-time employees. The company went IPO on 2000-03-27. The firm partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. The company provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. The company is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
Recently from Cashu
U.S. jobs and inflation test Edwards Lifesciences as hospital budgets squeeze device demand
U.S. jobs and inflation reports put medical device demand in focus Main topic — Hospitals’ budgets and capital spending shape Edwards’ near-term outlook Edwards Lifesciences faces a near-term demand t…
Fed jobs and inflation data could alter hospital capital plans, affecting Edwards Lifesciences' valve market
Fed-driven data may alter hospital capital plans for Edwards Lifesciences U.S. jobs and inflation releases scheduled together next week are putting the Federal Reserve’s path back at the centre of hos…
Edwards Lifesciences' Stock Gains Amid Zydus Lifesciences' Strategic Biologics Manufacturing Expansion
Zydus Lifesciences Expands Biologics Manufacturing with Strategic Acquisition Zydus Lifesciences Limited recently concludes a significant strategic move by finalizing an Asset Purchase Agreement, Shar…
Edwards Lifesciences' Zydus Expands Biologics Manufacturing with Agenus Acquisition
Zydus Lifesciences Strengthens Biologics Manufacturing Capabilities with Acquisition of Agenus Assets Zydus Lifesciences Limited, a prominent player in the life sciences sector, makes a significant mo…